XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units
01 févr. 2024 20h46 HE
|
XORTX Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 01, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the...
XORTX Announces $2 Million Public Offering
15 janv. 2024 07h00 HE
|
XORTX Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Jan. 15, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the...
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
03 janv. 2024 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Welcomes New Member to the Board of Directors
02 janv. 2024 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces US ATM Offering
30 nov. 2023 07h30 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 30, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Meets Nasdaq Continued Listing Requirements
29 nov. 2023 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Clarifies Timing for Share Consolidation
10 nov. 2023 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Share Consolidation
08 nov. 2023 17h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 08, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023
02 nov. 2023 07h00 HE
|
XORTX Therapeutics Inc.
● Preclinical Findings Help Clarify and Reinforce the Role of Uric Acid in the Pathogenesis of Polycystic Kidney Disease and the Potential of XORTX’s Proprietary Formulation of Oxypurinol as...
XORTX Announces Results of Special Meeting of Shareholders
27 oct. 2023 17h30 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 27, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...